The outcomes of lung sarcoidosis are affected by age, gender, race, incomes, environment, lung morbidity, lung leucocyte infiltration, requirement of treatment, and genetic variants of associated genes (e.g., human leucocyte antigen class II (HLA class II), tumor necrosis factor α (TNF-α) and annexin XI (ANXA11), among others) (1, 2). This evidence concerns the gene TNF and sarcoidosis.